Embracing Neurodiversity in Psychedelic Science: A Mixed-Methods Inquiry into the MDMA Experiences of Autistic Adults
This retrospective survey (n=100) and qualitative interview (n=24) study examined the MDMA experiences of autistic adults and identified that many of them viewed MDMA as a transformative healing catalyst for helping their anxieties of navigating through neurotypical social norms, while none of them expressed the desire for being neurotypical or reported being cured from autism.
Authors
- Alicia Danforth
Published
Abstract
Introduction
This exploratory inquiry analyzed subjective experiences autistic adults reported after they took the drug 3,4-methylenedioxymethamphetamine (MDMA), also known as ecstasy, in nonclinical settings.
Methods
Using a secure, globally available website, this study collected data from participants in 13 countries who were experienced with MDMA (n = 100). A subset of survey respondents (n = 24) were then invited to participate in qualitative interviews. The researcher applied thematic content analysis of interview transcripts to create a comprehensive account of emergent themes.
Results
MDMA has well-documented acute effects that promote pro-social attitudes such as caring and trust in neurotypical, or typically developing, populations. Findings from this study suggested that MDMA-assisted therapy may be an effective catalyst in autistic adults for intra- and interpersonal change. In addition, participants reported accounts of lasting transformation and healing from conditions such as trauma and social anxiety that are common in autistic populations. No participants reported long-term adverse outcomes as a result of using MDMA/ecstasy.
Discussion
Qualitative findings support a case for future clinical trials of MDMA-assisted therapy with autistic adults who present with social adaptability challenges.
Research Summary of 'Embracing Neurodiversity in Psychedelic Science: A Mixed-Methods Inquiry into the MDMA Experiences of Autistic Adults'
Introduction
Danforth conducted a preliminary, exploratory investigation into how autistic adults describe their subjective experiences after taking 3,4-methylenedioxymethamphetamine (MDMA, also called ecstasy or Molly) in non-clinical settings. The study responds to a gap in the literature: prior to this work there were no published clinical trials of MDMA with adult autistic populations, and little was known about whether MDMA's well‑documented empathogenic and pro‑social acute effects in neurotypical samples might have relevance for autistic adults who commonly experience social anxiety, trauma, and difficulties with social adaptability. The primary aims were to document emergent experiential themes from autistic adults who had used MDMA, to identify themes of clinical relevance for potential future investigations (including MDMA‑assisted therapy), and to include neurodivergent perspectives in the emerging MDMA research agenda. The study used a mixed‑methods approach, combining an online quantitative survey of MDMA‑experienced autistic adults with in‑depth semi‑structured interviews of a purposive subsample to generate rich qualitative data for thematic analysis.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Author
- APA Citation
Danforth, A. L. (2019). Embracing Neurodiversity in Psychedelic Science: A Mixed-Methods Inquiry into the MDMA Experiences of Autistic Adults. Journal of Psychoactive Drugs, 51(2), 146-154. https://doi.org/10.1080/02791072.2019.1587116
References (10)
Papers cited by this study that are also in Blossom
Danforth, A. L., Struble, C., Yazar-Klosinski, B. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2016)
Danforth, A. L., Grob, C. S., Struble, C. et al. · Psychopharmacology (2018)
Halpern, J. H., Sherwood, A. R., Hudson, J. I. et al. · Addiction (2011)
Johansen, P. Ø., Krebs, T. S. · Journal of Psychopharmacology (2009)
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T. et al. · Journal of Psychopharmacology (2010)
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T. et al. · Journal of Psychopharmacology (2012)
Mithoefer, A. T., Mithoefer, M. C., Feduccia, A. A. et al. · Lancet Psychiatry (2018)
Nichols, D. E. · Journal of Psychoactive Drugs (1986)
Vizeli, P., Liechti, M. E. · Journal of Psychopharmacology (2017)
Vollenweider, F. X., Gamma, A., Liechti, M. et al. · Neuropsychopharmacology (1998)
Cited By (3)
Papers in Blossom that reference this study
Ermakova, A. O., Dunbar, F., Seynaeve, M. et al. · Scientific Reports (2025)
Chaliha, D., Mamo, J. C., Albrecht, M. et al. · Current Neuropharmacology (2021)
de Wit, H., Bershad, A. K., Grob, C. S. · Journal of Psychopharmacology (2021)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.